Skip to main content
. 2024 Aug 28;7(1):149–159. doi: 10.1159/000540978

Fig. 2.

Fig. 2.

General health outcome measures reported by participants at 3 months (N = 58) and 6 months (N = 34) after starting treatment with CBMP. a General health self-reported by patients measured as the average scoring of the visual analogue scale (0–100) of the EQ-5D questionnaire (χ2 = 16.8, p < 0.001). b Health-related quality of life reported as the sum of the five levels of the EQ-5D (χ2 = 5.0, p = 0.082). c Effect in general mood/anxiety captured with the PHQ-9 questionnaire (χ2 = 18.4, p < 0.001). d Effect in sleep quality reported by participants filling the PSQI (χ2 = 20.3, p < 0.001).